Better Edge : A Northwestern Medicine podcast for physicians
Better Edge : A Northwestern Medicine podcast for physicians
PSMA-Targeted PET Imaging for Prostate Cancer
Loading
/
  • LISTEN ON:
  • Listen on Spotify
  • Listen on iHeart
  • Listen on Apple Podcasts
  • Listen on Google Podcasts
  • Listen on TuneIn
  • Listen on Stitcher
Placeholder Ad
Placeholder Ad
Placeholder Ad
Placeholder Ad

PSMA-Targeted PET Imaging for Prostate Cancer

psma-targeted-pet-imaging-for-prostate-cancerThe FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern Memorial Hospital is the first site in the Chicagoland market to perform prostate imaging using the this agent. What makes this approval so exciting, how will it change the field? How will it improve the diagnosis and treatment of prostate cancer patients?

Edward Schaeffer MD, PhD, Ashley Ross MD, PhD and Hatice Savas MD discuss PET PSMA imaging for prostate cancer the recent FDA approval of Pylarify for prostate cancer detection.

Pericardial Disease: Its Prevalence and the Role of Multidisciplinary Care

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen

Northwestern Medicine Geriatrics Home Care Program

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen

Continuity Matters: Transitioning Pediatric Patients to Adult Specialists

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen

The Connection Between Diabetes and Heart Disease

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen

Socioeconomic Status and Readmission After Acute Type A Aortic Dissection Repair

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen

Highlights from AAN 2024

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen

From Brain to Liver: Advances in Wilson Disease Management

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen

First Seizure Clinic

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen

Seizure Solutions: Inside the Northwestern Medicine First Seizure Clinic

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen

Advancing LGBTQ+ Diversity, Equity and Inclusion in Ophthalmology

The FDA recently approved PSMA PET imaging agent 18F-DCFPyL (Pylarify) for identifying suspected metastasis or recurrence of prostate cancer. Northwestern ...

Listen